China PD-1 inhibitors have boosted survival rates for many cancer patients since their introduction in the US five years ago. Last year, MSD and BMS began selling these expensive therapies in China, but local players are already releasing their own drugs, sometimes at a third of the price. This represents a…

China More accessible and affordable healthcare for all: China’s government has outlined several proposals to expand healthcare reform in a report released 4th June by the General Office of the State Council. These proposals include improving disease and treatment systems, expanding rural healthcare, and reforming hospital management and pricing.    Health…

China The pharmaceutical industries of China and India, historically focused on their large domestic markets and exports to developed nations, are increasingly forging closer links. With US trade tariffs affecting both countries and regulatory reform underway in China, Indian firms are jumping at the chance to bring their competitively-priced drugs to…

China The company sold 551 million shares in the latest IPO on the Hong Kong Exchange and plans to invest half of its earnings in R&D. Hong Kong is now the second largest biotech funding hub in the world.    Hansoh Pharmaceutical, one of China’s fastest-growing pharma companies, raised a billion…

Hong Kong With Hong Kong now established as the world’s second largest funding hub for biotech, at this week’s BIO 2019 conference in Philadelphia, the HKEX’s Michael Chan outlined some of the successes that the Hong Kong exchange has already seen and the exciting and diverse future listings in the pipeline.  …

China China is a hot topic in Big Pharma investor updates these days. The world’s second-largest pharmaceutical market boasts sales growth that continuously surpasses that of the US and other developed regions. However, with the rollout of the “4+7” procurement scheme slashing drug prices, industry insiders are predicting a more turbulent…

Biotech Hong Kong is now the world’s second largest funding hub for biotech according to Hong Kong Chief Executive Carrie Lam. During her speech at the 2nd HKEx Biotech Summit on May 29, Lam stated that innovation and technology have become a clear priority in government policy.   We have invested…

China On May 30th, and with much fanfare, Pfizer Upjohn officially inaugurated its global headquarters in the heart of Shanghai, China. Following a global re-organization mid-2018, Pfizer now operates three business units, namely Innovative Medicines (including biosimilars and a new hospital business unit dealing with anti-infectives and sterile injectables), Consumer Healthcare,…

China Better known for its panda sanctuary and spicy local cuisine, Chengdu could be the first Chinese city to offer mutual health insurance. Eric Bouteiller examines French firm VYV’s first steps into China and the potential impact of mutual insurance – whereby the insurance company is owned entirely by its policyholders…

China Amidst the sea of Big Pharma executives jumping ship to start highly regarded and attention-grabbing biotech companies, bolstered by the huge influx of capital, the opening of stock exchanges in first Hong Kong and subsequently Shanghai to pre-profit biotech companies that meet certain criteria, as well as the reformation and…

China Click here to register and download PharmaBoardroom’s latest report: Healthcare & Life Sciences Review: China.   From the world’s ninth largest pharma market in 2007 to its second-biggest merely 12 years later, China and its growth story are impossible to ignore. China now accounts for a significant share of revenues…

China China’s unbridled growth has spurred a vast number of overseas Chinese to return home to seek new opportunities in their transformed homeland. Affectionately known as ‘sea turtles’ because the Chinese characters for ‘returning from overseas’ are homonyms for the Chinese characters for ‘sea turtles’, this influx has ignited the country’s…